| [1] | SHANKAR-HARI M, PHILLIPS G S, LEVY M L, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock(sepsis-3)[J]. JAMA, 2016, 315(8): 775-787. doi: 10.3410/f.726165854.793550943 |
| [2] | GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050[J]. Lancet, 2024, 404(10459): 1199-1226. doi: 10.1016/S0140-6736(24)01867-1 |
| [3] | RUDD K E, JOHNSON S C, AGESA K M, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020, 395(10219): 200-211. doi: 10.1016/S0140-6736(19)32989-7 |
| [4] | TSAI I T, SUN C K. Stem cell therapy against ischemic heart disease[J]. Int J Mol Sci, 2024, 25(7): 3778. doi: 10.3390/ijms25073778 |
| [5] | HOUKIN K, OSANAI T, UCHIYAMA S, et al. Allogeneic stem cell therapy for acute ischemic stroke: the phase 2/3 TREASURE randomized clinical trial[J]. JAMA Neurol, 2024, 81(2): 154-162. doi: 10.1001/jamaneurol.2023.5200 |
| [6] | SHI L, ZHANG Z Y, MEI S, et al. Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights[J]. Signal Transduct Target Ther, 2025, 10(1): 238. doi: 10.1038/s41392-025-02318-4 |
| [7] | WANG Y J, MENG Z L, LIU M, et al. Autologous transplantation of P63(+)lung progenitor cells for chronic obstructive pulmonary disease therapy[J]. Sci Transl Med, 2024, 16(734): eadi3360. doi: 10.1126/scitranslmed.adi3360 |
| [8] | DANIEL M, BEDOUI Y, VAGNER D, et al. Pathophysiology of sepsis and genesis of septic shock: the critical role of mesenchymal stem cells(MSCs)[J]. Int J Mol Sci, 2022, 23(16): 9274. doi: 10.3390/ijms23169274 |
| [9] | CHEN G F, GUO Y E, LI C, et al. Small molecules that promote self-renewal of stem cells and somatic cell reprogramming[J]. Stem Cell Rev Rep, 2020, 16(3): 511-523. doi: 10.1007/s12015-020-09965-w |
| [10] | 韩韦钰, 赵永超, 赵然尊. mRNA m6A甲基化修饰对干细胞生物学特性的影响[J]. 中国组织工程研究, 2023, 27(10): 1584-1592. |
| [11] | TIAN Z Y, YU T, LIU J, et al. Introduction to stem cells[M]//Stem Cell in Medicine. Amsterdam: Elsevier, 2023: 3-32. |
| [12] | LIESVELD J L, SHARMA N, ALJITAWI O S. Stem cell homing: From physiology to therapeutics[J]. Stem Cells, 2020, 38(10): 1241-1253. doi: 10.1002/stem.3242 |
| [13] | ALI F, TARESH S, AL-NUZAILY M, et al. Stem cells differentiation and probing their therapeutic applications in hematological disorders: a critical review[J]. Eur Rev Med Pharmacol Sci, 2016, 20(20): 4390-4400. |
| [14] | KESHAVARZ SHAHBAZ S, MANSOURABADI A H, JAFARI D. Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease[J]. Clin Exp Immunol, 2022, 208(1): 12-24. doi: 10.1093/cei/uxac016 |
| [15] | XIA L J, ZHANG C L, LV N Y, et al. AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages[J]. Theranostics, 2022, 12(6): 2928-2947. doi: 10.7150/thno.69533 |
| [16] | WEN F L, YANG G K, YU S H, et al. Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties[J]. Stem Cell Res Ther, 2024, 15(1): 320. doi: 10.1186/s13287-024-03943-6 |
| [17] | KIM J H, GREEN D S, JU Y M, et al. Identification and characterization of stem cell secretome-based recombinant proteins for wound healing applications[J]. Front Bioeng Biotechnol, 2022, 10: 954682. doi: 10.3389/fbioe.2022.954682 |
| [18] | AQDAS M, SINGH S, AMIR M, et al. Cumulative signaling through NOD-2 and TLR-4 eliminates the Mycobacterium tuberculosis concealed inside the mesenchymal stem cells[J]. Front Cell Infect Microbiol, 2021, 11: 669168. doi: 10.3389/fcimb.2021.669168 |
| [19] | SHEN K, WANG X J, WANG Y W, et al. miR-125b-5p in adipose derived stem cells exosome alleviates pulmonary microvascular endothelial cells ferroptosis via Keap1/Nrf2/GPX4 in sepsis lung injury[J]. Redox Biol, 2023, 62: 102655. doi: 10.1016/j.redox.2023.102655 |
| [20] | SATO Y, OCHIAI D, ABE Y, et al. Prophylactic therapy with human amniotic fluid stem cells improved survival in a rat model of lipopolysaccharide-induced neonatal sepsis through immunomodulation via aggregates with peritoneal macrophages[J]. Stem Cell Res Ther, 2020, 11(1): 300. doi: 10.1186/s13287-020-01809-1 |
| [21] | KHOSROJERDI A, SOUDI S, HOSSEINI A Z, et al. The combination of mesenchymal stem cell- and hepatocyte-derived exosomes, along with imipenem, ameliorates inflammatory responses and liver damage in a sepsis mouse model[J]. Life Sci, 2023, 326: 121813. doi: 10.1016/j.lfs.2023.121813 |
| [22] | SRDIĆ T, ĐURAŠEVIĆ S, LAKIĆ I, et al. From molecular mechanisms to clinical therapy: understanding sepsis-induced multiple organ dysfunction[J]. Int J Mol Sci, 2024, 25(14): 7770. doi: 10.3390/ijms25147770 |
| [23] | AKHONDZADEH F, KADKHODAEE M, SEIFI B, et al. Adipose-derived mesenchymal stem cells and conditioned medium attenuate the memory retrieval impairment during sepsis in rats[J]. Mol Neurobiol, 2020, 57(9): 3633-3645. doi: 10.1007/s12035-020-01991-6 |
| [24] | LADDHA A P, KULKARNI Y A. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders[J]. Respir Med, 2019, 156: 33-46. doi: 10.1016/j.rmed.2019.08.003 |
| [25] | CÓNDOR J M, RODRIGUES C E, DE SOUSA MOREIRA R, et al. Treatment with human Wharton’s jelly-derived mesenchymal stem cells attenuates sepsis-induced kidney injury, liver injury, and endothelial dysfunction[J]. Stem Cells Transl Med, 2016, 5(8): 1048-1057. doi: 10.5966/sctm.2015-0138 |
| [26] | JERKIC M, LITVACK M L, GAGNON S, et al. Embryonic-derived myb(-)macrophages enhance bacterial clearance and improve survival in rat sepsis[J]. Int J Mol Sci, 2021, 22(6): 3190. doi: 10.3390/ijms22063190 |
| [27] | LUO C J, LUO F, CHE L, et al. Mesenchymal stem cells protect against sepsis-associated acute kidney injury by inducing Gal-9/Tim-3 to remodel immune homeostasis[J]. Ren Fail, 2023, 45(1): 2187229. doi: 10.1080/0886022X.2023.2187229 |
| [28] | JERKIC M, GAGNON S, RABANI R, et al. Human umbilical cord mesenchymal stromal cells attenuate systemic sepsis in part by enhancing peritoneal macrophage bacterial killing via heme oxygenase-1 induction in rats[J]. Anesthesiology, 2020, 132(1): 140-154. doi: 10.1097/ALN.0000000000003018 |
| [29] | WU Y F, ZHOU J, BI L Q, et al. Effects of bone marrow mesenchymal stem cells on the cardiac function and immune system of mice with endotoxemia[J]. Mol Med Rep, 2016, 13(6): 5317-5325. doi: 10.3892/mmr.2016.5151 |
| [30] | MIAO C M, JIANG X W, HE K, et al. Bone marrow stromal cells attenuate LPS-induced mouse acute liver injury via the prostaglandin E 2-dependent repression of the NLRP3 inflammasome in Kupffer cells[J]. Immunol Lett, 2016, 179: 102-113. doi: 10.1016/j.imlet.2016.09.009 |
| [31] | SATILMIS B, CICEK G S, CICEK E, et al. Adipose-derived stem cells in the treatment of hepatobiliary diseases and sepsis[J]. World J Clin Cases, 2022, 10(14): 4348-4356. doi: 10.12998/wjcc.v10.i14.4348 |
| [32] | ALP E, GONEN Z B, GUNDOGAN K, et al. The effect of mesenchymal stromal cells on the mortality of patients with sepsis and septic shock: a promising therapy[J]. Emerg Med Int, 2022, 2022: 9222379. doi: 10.1155/2022/9222379 |
| [33] | HE X, AI S M, GUO W, et al. Umbilical cord-derived mesenchymal stem(stromal)cells for treatment of severe sepsis: aphase 1 clinical trial[J]. Transl Res, 2018, 199: 52-61. doi: 10.1016/j.trsl.2018.04.006 |
| [34] | HAMILTON F, EVANS R, GHAZAL P, et al. Patients with transplantation have reduced mortality in bacteraemia: Analysis of data from a randomised trial[J]. J Infect, 2022, 85(1): 17-23. doi: 10.1016/j.jinf.2022.05.014 |
| [35] | WU Y J, LIU H X, ZHU X L, et al. Predicting short-term and long-term mortalities from sepsis in patients who receive allogeneic haematopoietic stem cell transplantation[J]. Br J Haematol, 2023, 202(2): 344-355. doi: 10.1111/bjh.18835 |
| [36] | AGHAYAN A H, MIRAZIMI Y, FATEH K, et al. Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in sepsis: a systematic review and meta-analysis of preclinical studies[J]. Stem Cell Rev Rep, 2024, 20(6): 1480-1500. doi: 10.1007/s12015-024-10741-3 |
| [37] | HOMMA K, BAZHANOV N, HASHIMOTO K, et al. Mesenchymal stem cell-derived exosomes for treatment of sepsis[J]. Front Immunol, 2023, 14: 1136964. doi: 10.3389/fimmu.2023.1136964 |
| [38] | LI S F, HAN Y, LU M X, et al. Mesenchymal stem cell-exosome-mediated matrix metalloproteinase 1 participates in oral leukoplakia and carcinogenesis by inducing angiogenesis[J]. J Oral Pathology Medicine, 2022, 51(7): 638-648. doi: 10.1111/jop.13321 |
| [39] | HAO X Y, GUO Y, WANG R, et al. Exosomes from adipose-derived mesenchymal stem cells promote survival of fat grafts by regulating macrophage polarization via let-7c[J]. Acta Biochim Biophys Sin, 2021, 53(4): 501-510. doi: 10.1093/abbs/gmab018 |
| [40] | YANG S J, ZHANG K L, HOU J Y, et al. Protective properties of extracellular vesicles in sepsis models: a systematic review and meta-analysis of preclinical studies[J]. J Transl Med, 2023, 21(1): 262. doi: 10.1186/s12967-023-04121-7 |
| [41] | WANG D F, XU L G, LIU Y K, et al. Role of mesenchymal stem cells in sepsis and their therapeutic potential in sepsis-associated myopathy(Review)[J]. Int J Mol Med, 2024, 54(5). DOI: 10.3892/ijmm.2024.5416. |
| [42] | KHOSROJERDI A, SOUDI S, HOSSEINI A Z, et al. Immunomodulatory and therapeutic effects of mesenchymal stem cells on organ dysfunction in sepsis[J]. Shock, 2021, 55(4): 423-440. doi: 10.1097/SHK.0000000000001644 |